Literature DB >> 3053802

Contact immunotherapy of resistant warts.

M F Naylor1, K H Neldner, G K Yarbrough, T J Rosio, M Iriondo, J Yeary.   

Abstract

Contact immunotherapy has been proved effective in the treatment of resistant warts. This report chronicles our experience with a new contact immunotherapy agent, diphenylcyclopropenone. We have achieved a cure rate of 62% in 45 patients with resistant warts of all types who came to our general dermatology clinic. Cure rates may be lower in patients who have experienced multiple treatment failures. The majority of cures were obtained within 3 to 4 months. Although it appears somewhat less effective than published reports of dinitrochlorobenzene contact immunotherapy, diphenylcyclopropenone contact immunotherapy is an effective treatment for resistant warts and avoids any potential problems from mutagenicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053802     DOI: 10.1016/s0190-9622(88)70222-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata.

Authors:  Kun-Wei Lai; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-22

Review 2.  [Papillomavirus diseases].

Authors:  U R Hengge
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

3.  Topical immunotherapy with diphenylcyclopropenone is effective and preferred in the treatment of periungual warts.

Authors:  Yunseok Choi; Do Hun Kim; Sang Yun Jin; Ai-Young Lee; Seung Ho Lee
Journal:  Ann Dermatol       Date:  2013-11-30       Impact factor: 1.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.